Clinical trials: Local Recurrence
Breast Cancer
Radiotherapy After Mastectomy for Breast Cancer Patients at Increased Risk of Local Recurrence
STUDY DESCRIPTION: This is a single-arm study to assess the feasibility, toxicity and cosmetic outcome of partial radiotherapy of the chest wall in breast cancer patients at increased risk of local relapse submitted to…
- Trial name
- NCT03101683
- Testing
- Partial chest wall radiation therapy
- Volunteers
- 28 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Prostate Cancer
Prospective Study Using Hybrid PET/MRI to Evaluate Men With Suspected Recurrence Following Treatment for Prostate Cancer
Evaluate the impact of hybrid 18F-Fluoro-choline (18F-FCH) PET/MRI imaging on the clinical management of men with suspected recurrent prostate cancer post prostatectomy or radiotherapy.
- Trial name
- IGPC-3 (NCT01804231)
- Testing
- 18F-FCH PET/MRI imaging
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01090466
- Testing
- cisplatin, gemcitabine hydrochloride, temsirolimus
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Cardiff University
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma
- Trial name
- NCT00049023
- Testing
- 90Y-DOTA-tyr3-OCTREOTIDE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- O'Dorisio, M S